Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
|Slideshows|June 26, 2018
- Dermatology Times, July 2018 (Vol. 39, No. 07)
- Volume 39
- Issue 7
Four questions every provider should ask about digital technology
Author(s)Dermatology Times Staff
There are four questions physicians should ask when considering using digital healthcare technologies, says Michael L. Hodgkins, M.D., chief medical officer for the American Medical Association. View the slideshow for more information.
Advertisement
There are four questions physicians should ask when considering using digital healthcare technologies, says Michael L. Hodgkins, M.D., chief medical officer for the American Medical Association. View the slideshow for more information.See:Â "More patients want digital health"Â
Articles in this issue
over 8 years ago
Pricing patients out of healthcare?over 8 years ago
Image IQ: When is a biopsy required?over 8 years ago
Rare tumors and fibrotic skin lesionsover 8 years ago
New Drugs Roundup: Dermatologyover 8 years ago
The top 7 mobile apps in dermatologyover 8 years ago
Medicine no longer apoliticalover 8 years ago
I use social media and now I might lose my license?over 8 years ago
Complications low with chemical peels in darker skinAdvertisement
Related to this article
Dermatology Times is looking back on the top stories in dermatology from the month of October.
From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Advertisement
Advertisement